ABSTRACT
Efficacy based on haemoglobin A1c (HbA1c) lowering and tolerability are no longer the only criteria for the success of a new drug for type 2 diabetes; ease of administration, convenient dosing, weight reductions or weight neutrality, a low hypoglycaemic risk and beneficial effects on cardiovascular outcomes are all important factors.
